It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Prevention of Stroke Recurrence in Patients with Embolic Stroke Study

Clinical Trial Title: 
Randomized evaluation in secondary stroke prevention comparing dabigatran extexilate versus aspirin in embolic stroke of undetermined source.
Clinical Trial Protocol ID: 
14062402
Clinical Trial Investigator Name: 
James Conners, MD
Clinical Trial Protocol Description: 

The purpose of this study is to compare the efficacy of the thrombin inhibitor dabigatran etexilate versus aspirin for the prevention of stroke recurrence in patients with embolic stroke of undetermined source.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be ≥ 60 years of age.
  • Have at least one of the following if you are 18-59 years of age:
    • Mild to moderate heart failure
    • Diabetes mellitus
    • Hypertension
    • Patent foramen ovale
    • Prior stroke or TIA

You will be excluded from the study if any of the following criteria apply to you:

  • Are at major risk cardioembolic source of embolism.
  • Have a history of atrial fibrillation.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Stroke and Cerebrovascular Disease
Contact Phone: 
(312) 563-2208
Contact Name: 
Tiffany Singson